What OrganaBio’s Excellos asset acquisition reveals about next-generation CDMO demand

Cell therapy needs redundancy, not just cleanrooms. OrganaBio’s Excellos deal tests whether bicoastal CDMO scale can reduce developer risk.

Cell therapy needs redundancy, not just cleanrooms. OrganaBio’s Excellos deal tests whether bicoastal CDMO scale can reduce developer risk.

Legacy’s new AUA-aligned vasectomy platform combines sperm banking and mail-in PVSA—find out how it could reshape male fertility care in the U.S.